This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Follow-up Study to Previous CARE Trial

This study has been completed.
Information provided by:
Bracco Diagnostics, Inc Identifier:
First received: May 23, 2007
Last updated: September 29, 2009
Last verified: September 2009
To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as >25% increase in SCr or >25% increase in cystatin C).

Condition Intervention
Moderate to Severe Chronic Kidney Disease Drug: iodinated contrast agent

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: CARE (Visipaque 320 and Isovue 370 in Cardiac Angiography in REnally Impaired Patients); FOLLOW-UP STUDY

Further study details as provided by Bracco Diagnostics, Inc:

Enrollment: 294
Study Start Date: June 2007
Study Completion Date: April 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
Drug: iodinated contrast agent
iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria: (from previous CARE trial)

  • • Screening eGFR between 20 and 59 mL/min/1.73m2

    • Baseline SCr obtained within 72 hours and before hydration or, if obtained after hydration started, had the screening blood sample obtained within 72 hours of contrast administration
    • At least one post dose blood sample available
    • Received randomized contrast agent
    • Underwent only one cardiac angiography procedure (diagnostic cardiac angiography followed by PCI was considered as one procedure if confirmed by investigator and total duration does not exceed 12 hours), then for this study
    • Provides written Informed Consent and is willing to comply with protocol requirements;
    • Was included in the patient list provided by Bracco;
    • At least 1 year has passed since the patient's participation ended in the original CARE trial, as determined from the list provided by Bracco

Exclusion Criteria:

  • • Screening eGFR outside the range of 20 and 59 mL/min/1.73m2

    • Unstable kidney disease or requiring dialysis upon enrollment
    • Prior to the post-dose blood draw, suffered a critical clinical event that would affect the reliability of serological measurement of renal function
    • Did not receive randomized contrast agent per CARE protocol
    • Did not undergo a cardiac angiography procedure per CARE protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00479024

United States, Alabama
Cardiovascular Associates
Birmingham, Alabama, United States, 35209
Sponsors and Collaborators
Bracco Diagnostics, Inc
Study Chair: Steven Sireci, M.D. Bracco Diagnostics, Inc
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Steven Sireci, Executive Director, Corporate medical Support, Bracco Diagnostics, Inc. Identifier: NCT00479024     History of Changes
Other Study ID Numbers: IOP112
Study First Received: May 23, 2007
Last Updated: September 29, 2009

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency processed this record on September 21, 2017